Palisade Bio (PALI) EBIT Growth (3y) (2013 - 2026)

Palisade Bio (PALI) EBIT Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 8.36%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 89.72%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 44.54%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -26.00%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -18.82%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 44.34%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 81.27%
10 Palisade Bio 372.94 Mn 247.74 Mn - -47.99%

Historic Data

Download Data
DateValue
Jun 30, 2026 -47.99%
Mar 31, 2026 -61.98%
Dec 31, 2025 -37.40%
Sep 30, 2025 12.84%
Jun 30, 2025 7.33%
Mar 31, 2025 15.93%
Dec 31, 2024 5.65%
Sep 30, 2024 -6.01%
Jun 30, 2024 49.58%
Mar 31, 2024 -23.41%
Dec 31, 2023 0.94%
Sep 30, 2023 -27.66%
Jun 30, 2023 -25.15%
Mar 31, 2023 -8.31%
Dec 31, 2022 -21.74%
Sep 30, 2022 -27.60%
Jun 30, 2022 -23.02%
Mar 31, 2022 -16.54%
Dec 31, 2021 -30.67%
Sep 30, 2021 -13.14%